EUVIMEDEUVIMED entdecken
Multizentrische StudieValidierungsstudie

Development and Validation of a Novel Model to Discriminate Idiosyncratic Drug‐Induced Liver Injury and Autoimmune Hepatitis

Yu Wang, Xuhui Lin, Ying Sun, Jimin Liu, Jia Li iD, Qiuju Tian, Feng Guo, Xiaoli Hu, Liang Wang, Pingying Li, Jingshou Chen, Yan Wang und 5 weitere

Liver International · 2025-02 · 45 (2)

DOI: 10.1111/liv.16239 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Liver International, online erschienen am 16.01.2025. Verfasst von Yu Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Hepatitis, Autoimmune, Chemical and Drug Induced Liver Injury, Machine Learning. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Discriminating between idiosyncratic drug‐induced liver injury (DILI) and autoimmune hepatitis (AIH) is critical yet challenging. We aim to develop and validate a machine learning (ML)‐based model to aid in this differentiation.

Methods

This multicenter cohort study utilised a development set from Beijing Friendship Hospital, with retrospective and prospective validation sets from 10 tertiary hospitals across various regions of China spanning January 2009 to May 2023. Different ML algorithms were tested using 24 routine laboratory parameters. The Shapley Additive exPlanations (SHAP) analysis was used to evaluate the contribution of each parameter in the ML model.

Results

A total of 2554 patients (1750 for DILI and 804 for AIH) were included. Using Gradient Boost Decision Tree algorithm, five key parameters—aspartate transaminase, globulin, prealbumin, creatinine and platelet count—were selected to construct the ML model. Consequently, a web‐based tool named Beijing‐AID (BJ‐AID) was developed ( http://43.143.153.225:5000/ ). The BJ‐AID model demonstrated excellent discrimination performance, with an area under the receiver operating characteristic curve (AUROC) of 0.94 (95% CI, 0.902–0.975) in the development set, 0.91 (95% CI, 0.900–0.928) in all external validation sets and 0.93 (95% CI, 0.889–0.974) in a prospective validation set. Notably, the BJ‐AID model also effectively discriminated atypical cases, including drug‐induced autoimmune‐like hepatitis and AIH with the history of drug consumption, achieving an AUROC = 0.85 (95% CI, 0.742–0.949).

Conclusions

We successfully developed and validated a machine learning‐based model, BJ‐AID, which exhibits a strong discrimination performance. BJ‐AID can assist practitioners and hepatologists in diagnosing both typical and atypical cases of DILI and AIH. Trial Registration ClinicalTrials.gov identifier: NCT05532345

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis, AutoimmuneChemical and Drug Induced Liver InjuryMachine LearningHumansFemaleMaleMiddle AgedProspective StudiesAdultRetrospective StudiesChinaDiagnosis, DifferentialROC CurveAlgorithmsAspartate AminotransferasesAgedDecision Trees

Stichwörter der Autor:innen

artificial intelligenceautoimmune liver diseasesdifferentiate diagnosisdrug toxicity

Substanzen

Aspartate Aminotransferases

Autor:innen und Institutionen

  • Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • State Key Laboratory of Digestive Health and National Clinical Research Center of Digestive Disease, Beijing, China.
  • The Bartlett School of Sustainable Construction, Faculty of the Built Environment, University College London, London, UK.
  • Department of Hepatology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
  • Department of Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada.
  • Department of Hepatology, Tianjin Second People's Hospital, Tianjin, China.

ORCID-Profile: Jia Li, Zhengsheng Zou, Xinyan Zhao

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Wang, Y., Lin, X., Sun, Y., Liu, J., Li, J., Tian, Q., Guo, F., Hu, X., Wang, L., Li, P., Chen, J., Wang, Y., Ma, Z., Jia, J., Zhang, J., Zou, Z., & Zhao, X. (2025). Development and Validation of a Novel Model to Discriminate Idiosyncratic Drug‐Induced Liver Injury and Autoimmune Hepatitis. Liver International, 45(2). https://doi.org/10.1111/liv.16239

Vancouver

Wang Y, Lin X, Sun Y, Liu J, Li J, Tian Q, et al. Development and Validation of a Novel Model to Discriminate Idiosyncratic Drug‐Induced Liver Injury and Autoimmune Hepatitis. Liver International. 2025;45(2). doi:10.1111/liv.16239

BibTeX
@article{Wang2025,
  author = {Wang, Yu and Lin, Xuhui and Sun, Ying and Liu, Jimin and Li, Jia and Tian, Qiuju and Guo, Feng and Hu, Xiaoli and Wang, Liang and Li, Pingying and Chen, Jingshou and Wang, Yan and Ma, Zikun and Jia, Jidong and Zhang, Jing and Zou, Zhengsheng and Zhao, Xinyan},
  title = {Development and Validation of a Novel Model to Discriminate Idiosyncratic Drug‐Induced Liver Injury and Autoimmune Hepatitis},
  journal = {Liver International},
  year = {2025},
  volume = {45},
  number = {2},
  doi = {10.1111/liv.16239}
}
Kostenlos starten →